Category: 1089279-91-3

Chemistry is traditionally divided into organic and inorganic chemistry. category: piperidines. The former is the study of compounds containing at least one carbon-hydrogen bonds.In a patent，Which mentioned a new discovery about 1089279-91-3

The present invention provides a process for the preparation of. a compound of formula I (I) in the form of a compound. (by machine translation)

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.category: piperidines, you can also check out more blogs about1089279-91-3

Reference：
Piperidine – Wikipedia,
Piperidine | C5H20772N – PubChem

 

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent， SDS of cas: 1089279-91-3, Which mentioned a new discovery about 1089279-91-3

The present invention relates to a N2,N4-diphenylpyrimidin-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for the prevention or treatment of cancer, containing the same as an active ingredient. The derivative shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a high inhibitory ability on EGFR mutation, and a high inhibitory ability on even FLT3 and FLT3 mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation or cancer with FLT3 or a mutation thereof, and the derivative shows a synergy effect at the time of combination administration, and thus can be effectively used for the treatment of combination administration.

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 1089279-91-3, help many people in the next few years.SDS of cas: 1089279-91-3

Reference：
Piperidine – Wikipedia,
Piperidine | C5H20769N – PubChem

 

Synthetic Route of 1089279-91-3, Catalysts are substances that increase the reaction rate of a chemical reaction without being consumed in the process. 1089279-91-3, Name is 1-(4-Amino-3-methoxyphenyl)-N,N-dimethylpiperidin-4-amine, molecular formula is C14H23N3O. In a Patent，once mentioned of 1089279-91-3

Disclosed is a preparation method for an antitumor drug AP26113 (I). The method comprises the following preparation steps: cyclizing N-[2-methoxyl-4[4-(dimethyl amino)piperid-1-yl]aniline]guanidine and N,N-dimethylamino acrylate, condensing N-[2-methoxyl-4[4-(dimethyl amino)piperid-1-yl]aniline]guanidine and 4-(dimethyl phosphitylate)aniline, and chlorinating N-[2-methoxyl-4[4-(dimethyl amino)piperid-1-yl]aniline]guanidine and a chlorinating agent, sequentially, so as to prepare AP26113 (I). The preparation method adopts easily-obtained raw materials, causes few side reactions, and is economical, environmentally friendly, and suitable for industrial production.

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. Synthetic Route of 1089279-91-3, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 1089279-91-3, in my other articles.

Reference：
Piperidine – Wikipedia,
Piperidine | C5H20781N – PubChem

 

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 1089279-91-3, name is 1-(4-Amino-3-methoxyphenyl)-N,N-dimethylpiperidin-4-amine, introducing its new discovery. COA of Formula: C14H23N3O

This application pertains to the medical field, specifically relates to as tyrosine kinase inhibitors of the boron-containing compound, preparation method thereof, a pharmaceutical composition containing the compound, and its use in the treatment of tyrosine kinase-mediated cell proliferative disorders. The application of the compound of the tyrosine kinase good inhibition effect. (by machine translation)

The proportionality constant is the rate constant for the particular unimolecular reaction. the reaction rate is directly proportional to the concentration of the reactant. I hope my blog about 1089279-91-3 is helpful to your research. COA of Formula: C14H23N3O

Reference：
Piperidine – Wikipedia,
Piperidine | C5H20766N – PubChem

 

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent， Recommanded Product: 1089279-91-3, Which mentioned a new discovery about 1089279-91-3

The invention of formula (I) compound and its pharmaceutical composition and preparation method, it can be used as ALK inhibitor for the treatment of diseases mediated by the ALK. The invention also of formula (I) compounds and pharmaceutical compositions thereof in the preparation of the treatment of diseases mediated by the ALK of application of the medicament. (by machine translation)

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, Recommanded Product: 1089279-91-3, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 1089279-91-3

Reference：
Piperidine – Wikipedia,
Piperidine | C5H20774N – PubChem

 

Chemistry is traditionally divided into organic and inorganic chemistry. Safety of 1-(4-Amino-3-methoxyphenyl)-N,N-dimethylpiperidin-4-amine. The former is the study of compounds containing at least one carbon-hydrogen bonds.In a patent£¬Which mentioned a new discovery about 1089279-91-3

PYRIMIDINE INHIBITORS OF KINASE ACTIVITY

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, R2, R3, R4, R5, n, p, q, Ar1, and Ar2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.Safety of 1-(4-Amino-3-methoxyphenyl)-N,N-dimethylpiperidin-4-amine, you can also check out more blogs about1089279-91-3

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H20767N – PubChem

 

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 1089279-91-3, name is 1-(4-Amino-3-methoxyphenyl)-N,N-dimethylpiperidin-4-amine, introducing its new discovery. Application In Synthesis of 1-(4-Amino-3-methoxyphenyl)-N,N-dimethylpiperidin-4-amine

PYRIMIDINE INHIBITORS OF KINASE ACT1VITY

Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, L1, R2, R3, n, p, Ar1, and Ar2 are defined in the description. Methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed

The proportionality constant is the rate constant for the particular unimolecular reaction. the reaction rate is directly proportional to the concentration of the reactant. I hope my blog about 1089279-91-3 is helpful to your research. Application In Synthesis of 1-(4-Amino-3-methoxyphenyl)-N,N-dimethylpiperidin-4-amine

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H20783N – PubChem

 

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1089279-91-3,1-(4-Amino-3-methoxyphenyl)-N,N-dimethylpiperidin-4-amine,as a common compound, the synthetic route is as follows.

To n-butanol (2 mL) was added compound 4A-5 (50 mg, 0.200 mmol) and compound 5A-2 (70 mg, 0.200 mmol), and then p-toluenesulfonic acid (35 mg, 0.200 mmol) was added under stirring. The mixture was heated to 100C and stirred for 5 hours. After TLC indicated the reaction was completed, the reaction mixture was concentrated under reduced pressure to give a crude product, which was further purified and isolated by column chromatography to obtain an off-white solid product, compound I-6 (78 mg, yield 69.4%). 1H NMR (400 MHz, cd3od) delta 9.11 (d, J=6.9 Hz, 1H), 8.36-8.31 (m, 1H), 8.09 (d, J=3.6 Hz, 1H), 7.58-7.45 (m, 2H), 6.67 (t, J=2.8 Hz, 1H), 6.57-6.50 (m, 1H), 3.92-3.76 (m, 6H), 3.40-3.31 (m, 1H), 2.90 (s, 6H), 2.79 (m, 2H), 2.18 (m, 2H), 1.87 (m, 2H), 1.29 (t, J=6.6 Hz, 6H). LCMS: t=0.807 min, 559.2 (M), 560.2 (M+1)

1089279-91-3, The synthetic route of 1089279-91-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Humanwell Healthcare (Group) Co., Ltd.; WANG, Xuehai; XU, Yong; SHENG, Xijun; ZHANG, Xiaolin; XIA, Hangui; YANG, Zhongwen; YUE, Yang; HUANG, Lu; XIAO, Qiang; (80 pag.)EP3372594; (2018); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem